# OneMedNet Corp: financial statements, quarterly

ONMD · Nasdaq · CIK 1849380 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/onmd.md) · [Financials](/companies/onmd/financials.md) · [Filings](/companies/onmd/filings.md) · [Insiders](/companies/onmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/onmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.3](/filings/0001493152-24-050454.md) | [0.3 d](/filings/0001641172-25-004815.md) | [0.2](/filings/0001641172-25-010321.md) | [0.2](/filings/0001641172-25-023557.md) | [0.1](/filings/0001493152-25-023544.md) | [0.0 d](/filings/0001493152-26-013681.md) | [0.1](/filings/0001493152-26-023801.md) | [0.2](/filings/0001493152-26-038461.md) | [0.2](/filings/0001493152-25-023544.md) | [0.9 d](/filings/0001493152-26-013681.md) | [0.1](/filings/0001493152-26-023801.md) | [0.3](/filings/0001493152-26-038461.md) |
| Cost of revenue | $m | [0.3](/filings/0001493152-24-050454.md) | [0.3 d](/filings/0001641172-25-004815.md) | [0.3](/filings/0001641172-25-010321.md) | [0.3](/filings/0001641172-25-023557.md) | [0.2](/filings/0001493152-25-023544.md) | [0.1 d](/filings/0001493152-26-013681.md) | [0.4](/filings/0001493152-26-023801.md) | [0.4](/filings/0001493152-26-038461.md) | [0.4](/filings/0001493152-25-023544.md) | [0.7 d](/filings/0001493152-26-013681.md) | [0.5](/filings/0001493152-26-023801.md) | [0.9](/filings/0001493152-26-038461.md) |
| Gross profit | $m | [0.0](/filings/0001493152-24-050454.md) | [0.0 d](/filings/0001641172-25-004815.md) | [(0.1)](/filings/0001641172-25-010321.md) | [(0.1)](/filings/0001641172-25-023557.md) | [(0.1)](/filings/0001493152-25-023544.md) | [(0.0) d](/filings/0001493152-26-013681.md) | [(0.2)](/filings/0001493152-26-023801.md) | [(0.2)](/filings/0001493152-26-038461.md) | [(0.2)](/filings/0001493152-25-023544.md) | [0.2 d](/filings/0001493152-26-013681.md) | [(0.4)](/filings/0001493152-26-023801.md) | [(0.6)](/filings/0001493152-26-038461.md) |
| Research and development | $m | [0.4](/filings/0001493152-24-050454.md) | [0.5 d](/filings/0001641172-25-004815.md) | [0.4](/filings/0001641172-25-010321.md) | [0.4](/filings/0001641172-25-023557.md) | [0.3](/filings/0001493152-25-023544.md) | [0.3 d](/filings/0001493152-26-013681.md) | [0.3](/filings/0001493152-26-023801.md) | [0.4](/filings/0001493152-26-038461.md) | [0.3](/filings/0001493152-25-023544.md) | [0.4 d](/filings/0001493152-26-013681.md) | [0.3](/filings/0001493152-26-023801.md) | [0.3](/filings/0001493152-26-038461.md) |
| Operating income | $m | [(1.9)](/filings/0001493152-24-050454.md) | [(1.9) d](/filings/0001641172-25-004815.md) | [(2.1)](/filings/0001641172-25-010321.md) | [(2.5)](/filings/0001641172-25-023557.md) | [(2.3)](/filings/0001493152-25-023544.md) | [(2.7) d](/filings/0001493152-26-013681.md) | [(2.2)](/filings/0001493152-26-023801.md) | [(2.1)](/filings/0001493152-26-038461.md) | [(2.2)](/filings/0001493152-25-023544.md) | [(3.1) d](/filings/0001493152-26-013681.md) | [(2.6)](/filings/0001493152-26-023801.md) | [(2.3)](/filings/0001493152-26-038461.md) |
| Interest expense | $m | not reported | [(0.5) d](/filings/0001493152-24-043625.md) | [0.0](/filings/0001493152-24-048874.md) | [0.0](/filings/0001493152-24-049637.md) | [0.0](/filings/0001493152-24-050454.md) | [0.1 d](/filings/0001493152-26-013681.md) | [0.0](/filings/0001493152-26-023801.md) | [0.0](/filings/0001493152-26-038461.md) | [0.0](/filings/0001493152-25-023544.md) | [0.0 d](/filings/0001493152-26-013681.md) | [0.0](/filings/0001493152-26-023801.md) | [0.0](/filings/0001493152-26-038461.md) |
| Income tax | $m | [0.1](/filings/0001493152-23-045125.md) | [(0.2) d](/filings/0001641172-25-004815.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(13.8)](/filings/0001493152-24-050454.md) | [(2.5) d](/filings/0001641172-25-004815.md) | [(2.1)](/filings/0001493152-25-023544.md) | [(3.6)](/filings/0001493152-25-023544.md) | [(2.1)](/filings/0001493152-25-023544.md) | [(2.4) d](/filings/0001493152-26-013681.md) | [(1.9)](/filings/0001493152-26-038461.md) | [3.0](/filings/0001493152-26-038461.md) | [(0.7)](/filings/0001493152-25-023544.md) | [(3.1) d](/filings/0001493152-26-013681.md) | [(2.5)](/filings/0001493152-26-038461.md) | [(2.2)](/filings/0001493152-26-038461.md) |
| Diluted EPS | $ per share | [(3.23)](/filings/0001493152-24-050454.md) | not reported | [(0.08)](/filings/0001641172-25-010321.md) | [(0.14)](/filings/0001641172-25-023557.md) | [(0.07)](/filings/0001493152-25-023544.md) | not reported | [(0.06)](/filings/0001493152-26-023801.md) | [0.07](/filings/0001493152-26-038461.md) | [(0.01)](/filings/0001493152-25-023544.md) | not reported | [(0.04)](/filings/0001493152-26-023801.md) | [(0.04)](/filings/0001493152-26-038461.md) |
| Basic EPS | $ per share | [(3.23)](/filings/0001493152-24-050454.md) | not reported | [(0.08)](/filings/0001641172-25-010321.md) | [(0.14)](/filings/0001641172-25-023557.md) | [(0.07)](/filings/0001493152-25-023544.md) | not reported | [(0.06)](/filings/0001493152-26-023801.md) | [0.07](/filings/0001493152-26-038461.md) | [(0.01)](/filings/0001493152-25-023544.md) | not reported | [(0.04)](/filings/0001493152-26-023801.md) | [(0.04)](/filings/0001493152-26-038461.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-21) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | period not labelled (2026-04-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001493152-24-043625.md) | [0.2](/filings/0001493152-24-048874.md) | [0.4](/filings/0001493152-24-049637.md) | [1.9](/filings/0001493152-24-050454.md) | [0.2](/filings/0001493152-26-013681.md) | [0.1](/filings/0001641172-25-010321.md) | [0.1](/filings/0001641172-25-023557.md) | [0.1](/filings/0001493152-25-023544.md) | [0.6](/filings/0001493152-26-038461.md) | [0.2](/filings/0001493152-26-023801.md) | not reported | [0.4](/filings/0001493152-26-038461.md) |
| Current assets | $m | [0.4](/filings/0001641172-25-004815.md) | [0.7](/filings/0001493152-24-048874.md) | [1.0](/filings/0001493152-24-049637.md) | [4.3](/filings/0001493152-24-050454.md) | [3.6](/filings/0001493152-26-013681.md) | [1.6](/filings/0001641172-25-010321.md) | [2.3](/filings/0001641172-25-023557.md) | [1.4](/filings/0001493152-25-023544.md) | [2.1](/filings/0001493152-26-038461.md) | [1.5](/filings/0001493152-26-023801.md) | not reported | [1.3](/filings/0001493152-26-038461.md) |
| Total assets | $m | [0.5](/filings/0001641172-25-004815.md) | [0.8](/filings/0001493152-24-048874.md) | [1.0](/filings/0001493152-24-049637.md) | [4.4](/filings/0001493152-24-050454.md) | [3.7](/filings/0001493152-26-013681.md) | [1.7](/filings/0001641172-25-010321.md) | [2.3](/filings/0001641172-25-023557.md) | [1.5](/filings/0001493152-25-023544.md) | [2.2](/filings/0001493152-26-038461.md) | [1.5](/filings/0001493152-26-023801.md) | not reported | [1.4](/filings/0001493152-26-038461.md) |
| Current liabilities | $m | [13.8](/filings/0001641172-25-004815.md) | [14.7](/filings/0001493152-24-048874.md) | [20.0](/filings/0001493152-24-049637.md) | [18.6](/filings/0001493152-24-050454.md) | [19.2](/filings/0001493152-26-013681.md) | [18.2](/filings/0001641172-25-010321.md) | [6.2](/filings/0001641172-25-023557.md) | [5.0](/filings/0001493152-25-023544.md) | [4.8](/filings/0001493152-26-038461.md) | [5.4](/filings/0001493152-26-023801.md) | not reported | [4.7](/filings/0001493152-26-038461.md) |
| Total liabilities | $m | [13.9](/filings/0001641172-25-004815.md) | [16.5](/filings/0001493152-24-048874.md) | [20.2](/filings/0001493152-24-049637.md) | [18.7](/filings/0001493152-24-050454.md) | [19.7](/filings/0001493152-26-013681.md) | [18.3](/filings/0001641172-25-010321.md) | [6.2](/filings/0001641172-25-023557.md) | [5.4](/filings/0001493152-25-023544.md) | [5.1](/filings/0001493152-26-038461.md) | [5.6](/filings/0001493152-26-023801.md) | not reported | [4.9](/filings/0001493152-26-038461.md) |
| Long-term debt | $m | [0.5](/filings/0001641172-25-004815.md) | not reported | [2.4](/filings/0001493152-24-049637.md) | [2.3](/filings/0001493152-24-050454.md) | [2.3](/filings/0001493152-25-023544.md) | [2.3](/filings/0001641172-25-010321.md) | not reported | not reported | [0.2](/filings/0001493152-26-038461.md) | [0.2](/filings/0001493152-26-023801.md) | not reported | [0.1](/filings/0001493152-26-038461.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | [9.4](/filings/0001493152-26-013681.md) | not reported | not reported | not reported | [1.0](/filings/0001493152-26-038461.md) | [0.8](/filings/0001493152-26-023801.md) | not reported | [0.7](/filings/0001493152-26-038461.md) |
| Short-term borrowings | $m | [0.5](/filings/0001641172-25-004815.md) | not reported | not reported | [2.3](/filings/0001493152-24-050454.md) | [2.3](/filings/0001493152-25-023544.md) | [2.3](/filings/0001641172-25-010321.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(13.4)](/filings/0001493152-26-013681.md) | [(15.7)](/filings/0001493152-25-023544.md) | [(19.2)](/filings/0001493152-25-023544.md) | [(14.3)](/filings/0001493152-25-023544.md) | [(16.0)](/filings/0001493152-26-038461.md) | [(16.6)](/filings/0001493152-26-038461.md) | [(3.8)](/filings/0001493152-26-038461.md) | [(3.9)](/filings/0001493152-25-023544.md) | [(3.0)](/filings/0001493152-26-038461.md) | [(4.1)](/filings/0001493152-26-038461.md) | [0.2](/filings/0001493152-26-038461.md) | [(3.5)](/filings/0001493152-26-038461.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,100) d](/filings/0001493152-24-050454.md) | [(1,725) d](/filings/0001641172-25-004815.md) | [(1,547)](/filings/0001641172-25-010321.md) | [(1,506) d](/filings/0001641172-25-023557.md) | [(1,903) d](/filings/0001493152-25-023544.md) | [(1,996) d](/filings/0001493152-26-013681.md) | [(1,854)](/filings/0001493152-26-023801.md) | [(2,189) d](/filings/0001493152-26-038461.md) | [(1,747) d](/filings/0001493152-25-023544.md) | [(1,713) d](/filings/0001493152-26-013681.md) | [(1,542)](/filings/0001493152-26-023801.md) | [(1,875) d](/filings/0001493152-26-038461.md) |
| Capital expenditure | $k | [21.0 d](/filings/0001493152-24-050454.md) | [16.0 d](/filings/0001641172-25-004815.md) | [6.0](/filings/0001641172-25-010321.md) | [1.0 d](/filings/0001641172-25-023557.md) | [9.0 d](/filings/0001493152-25-023544.md) | [35.0 d](/filings/0001493152-26-013681.md) | [5.0](/filings/0001493152-26-023801.md) | [3.0 d](/filings/0001493152-26-038461.md) | [0.0 d](/filings/0001493152-25-023544.md) | [5.0 d](/filings/0001493152-26-013681.md) | [2.0](/filings/0001493152-26-023801.md) | [9.0 d](/filings/0001493152-26-038461.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.0](/filings/0001493152-24-048874.md) | [4.0](/filings/0001493152-24-049637.md) | [4.3](/filings/0001493152-24-050454.md) | [24.9](/filings/0001641172-25-010321.md) | [25.2](/filings/0001641172-25-023557.md) | [29.3](/filings/0001493152-25-023544.md) | [34.1](/filings/0001493152-26-023801.md) | [38.4](/filings/0001493152-26-038461.md) | [52.6](/filings/0001493152-25-023544.md) | [55.3](/filings/0001493152-26-023801.md) | [58.0](/filings/0001493152-26-038461.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,286,450 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038461.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.